Growth Metrics

Protagonist Therapeutics (PTGX) Consolidated Net Income (2017 - 2025)

Historic Consolidated Net Income for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$39.3 million.

  • Protagonist Therapeutics' Consolidated Net Income fell 1845.53% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 7314.91%. This contributed to the annual value of $275.2 million for FY2024, which is 44853.78% up from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Consolidated Net Income is -$39.3 million, which was down 1845.53% from -$34.8 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Consolidated Net Income ranged from a high of $207.3 million in Q1 2024 and a low of -$41.0 million during Q2 2022
  • Over the past 5 years, Protagonist Therapeutics' median Consolidated Net Income value was -$33.2 million (recorded in 2024), while the average stood at -$7.5 million.
  • Per our database at Business Quant, Protagonist Therapeutics' Consolidated Net Income plummeted by 33545.02% in 2021 and then soared by 71479.61% in 2024.
  • Protagonist Therapeutics' Consolidated Net Income (Quarter) stood at -$37.2 million in 2021, then grew by 7.77% to -$34.3 million in 2022, then soared by 179.78% to $27.3 million in 2023, then skyrocketed by 381.7% to $131.7 million in 2024, then tumbled by 129.88% to -$39.3 million in 2025.
  • Its Consolidated Net Income stands at -$39.3 million for Q3 2025, versus -$34.8 million for Q2 2025 and -$11.7 million for Q1 2025.